Vaccine developer SK Bio heats up Korean market with IPO
![Covid_vaccine_575px_Adobe_26June20](https://assets.euromoneydigital.com/dims4/default/3358c19/2147483647/strip/true/crop/575x375+0+0/resize/840x548!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F3c%2F2d%2F761c0fee4671ab8509ffc1eb0e4e%2Fcovid-vaccine-575px-adobe-26june20.jpg)
SK Bioscience has priced its IPO at the top of the marketed range, raising W1.49tr ($1.32bn) from South Korea’s largest listing in four years.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: